Autres langues Revelation Biosciences, Inc.

Actions

REVB

US76135L8046

Recherche biotechnologique et médicale

Temps Différé Nasdaq 19:30:37 30/09/2026			Varia. 5j.	Varia. 1 janv.
0,8183 ^USD	+0,53%		-12,42%	-74,42%

19/08	Revelation Biosciences choisit Avance Clinical comme CRO pour l'étude de Phase 2/3 TITAN évaluant Gemini dans l'insuffisance rénale aiguë	CI
06/08	Revelation Biosciences, Inc. publie ses résultats pour le deuxième trimestre et le premier semestre clos le 30 juin 2026	CI

Autres langues

19/08	Revelation Biosciences Selects Avance Clinical as CRO for Phase 2/3 TITAN Study
19/08	Revelation Biosciences Selects Avance Clinical as Cro for Phase 2/3 Titan Study Evaluating Gemini in Acute Kidney Injury
06/08	Revelation Biosciences, Inc. Announces Financial Results for the Three and Six Months Ended June 30, 2026
06/08	Revelation Biosciences, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026
03/08	Independent Market Assessment Results Show $94 Billion Total Addressable Market for Gemini in Stage 2 and Stage 3 Acute Kidney Injury
21/07	Revelation Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
10/07	Revelation Biosciences Adopts Stockholder Rights Plan
10/07	Revelation Biosciences Announces Adoption of Stockholder Rights Plan
01/06	Revelation Biosciences Expands Acute Kidney Injury Advisory Board
11/05	Revelation Biosciences, Inc. Releases Corporate Update Letter to Stockholders
07/05	Revelation Biosciences, Inc. Announces Financial Results For the Three Months Ended March 31, 2026
07/05	Revelation Biosciences, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026
06/04	Revelation Biosciences Announces Formation of Acute Kidney Injury Advisory Board
30/03	Revelation Biosciences Inc. Presents Additional Positive Data from Prime Clinical Study
24/03	REMINDER: Revelation Biosciences to Host Fireside Chat at 38th Annual Roth Conference
19/03	Revelation Biosciences to Host Fireside Chat at 38th Annual Roth Conference
26/02	Revelation Biosciences, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025
26/02	Revelation Biosciences, Inc. Auditor Raises 'Going Concern' Doubt
26/01	Revelation Biosciences to Implement 1-for-4 Reverse Stock Split
26/01	American Lithium Minerals (OTC: AMLM) Accelerates Global Expansion Across Gold, Silver, Copper, Critical Minerals, and Rare Earth Elements
22/01	Revelation Biosciences, Inc. Reaches Agreement with FDA on Gemini Approval Pathway for ADA
27/11	Earnings Flash (REVB) Revolution Beauty Group Reports Fiscal H1 Revenue GBP49.4M
20/11	Revelation Says On Track for FDA Meeting Later This Year
06/11	Revelation Biosciences Q3 net loss narrows to $1.9 mln
06/11	Revelation Biosciences, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2025